Xcout Intel
ApoGlyx
ApoGlyx is a Swedish life science company located in Lund that focuses on developing innovative medicines for acute systemic inflammatory diseases such as sepsis and acute pancreatitis.
Subscribe to see ApoGlyx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ApoGlyx at a glance
ApoGlyx is a drug discovery company headquartered in Sweden. Its most recent funding round, Seed, raised $678,000 in October 2021. Xcout tracks 7 named people at ApoGlyx, including Michael Rützler (Chief Executive Officer).
ApoGlyx leadership
- Michael RützlerChief Executive Officer
- Preben Bruun-NyzellChairman of the board
- Søren NielsenCo-founder
- Andreas L. NorlinMember of the Board of Directors
- Anja HolmBoard Member
- Kenneth StokhomBoard Member
1 more named person on record for ApoGlyx, with roles, board committees and tenure — see the full roster →
ApoGlyx funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $678,000 | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
ApoGlyx competitors
A few of ApoGlyx's closest competitors — see the full list of competitors and alternatives →
Gesynta Pharma AB is a pharmaceutical manufacturing company headquartered in Stockholm, Sweden, dedicated to developing innovative anti-inflammatory and pain-relieving therapies targeting the mPGES-1 enzyme.
Vivacelle Bio, Inc. is a Chicago-based developmental-stage biotechnology company pioneering innovative intravenous fluid therapies for treating conditions like sepsis and organ failure.
MinervaX is a privately held biotechnology company headquartered in Copenhagen, Denmark, pursuing the development of a novel maternal prophylactic vaccine for the prevention of Group B Streptococcus disease.
AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company headquartered in Stockholm. The company focuses on developing novel drugs designed to treat heart failure.
NXI Therapeutics AG is a biotech company based in Basel, Switzerland, focused on researching and developing selective immunosuppressive drugs and immunotherapies for autoimmune diseases and transplantation.
Get ApoGlyx's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ApoGlyx in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access